We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CNBX Pharmaceuticals Inc (QB) | USOTC:CNBX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0022 | -16.92% | 0.0108 | 0.0001 | 0.018 | 0.01245 | 0.0107 | 0.01222 | 1,210,157 | 21:30:14 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 21, 2019
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Nevada | 333-192759 | 20-3373669 |
(State of incorporation) | (Commission File Number) | (IRS Employer No.) |
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices and Zip Code)
877 424-2429
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On June 21 st , 2019, the Board of Directors of the Corporation nominated two Independent Directors to its Board. The Independent Directors shall each be compensated with 125,000 Warrants, at a strike price of $.30. Said Warrants shall have a one-year life.
Dr. Estery Giloz-Ran, 45, has held the position of visiting Scholar at the Stern School of Business at New York University, Visiting Professor in the School of Business at the Yeshiva University, former Head of Accountancy at the Peres Academic Center’s School of Business, and is currently a Lecturer at the Bar Ilan University in Israel, Department of Economics and Accounting. Dr. Giloz-Ran is an External Director in several public companies including Blue Square Real Estate, Aran R&D, Oversiz, Suny, Kamada and is the Former Chairperson of the Board of Tamir Fishman, a known venture capital fund. Dr. Giloz-Ran is a licensed CPA, holds an MBA in Business Administration from Ben Gurion University, and a PhD in Tax, Accounting & Finance from Ben Gurion University
Eran Ballan
54,
brings executive management experience with large public entities in international markets. Mr. Ballan served as Partner, and Head
of the Biotech Department at Naschitz Brandeis, one of the largest law firms in Israel
.
Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv public company part of the
TA-35 and Real-Estate 15 index in Israel.
Mr. Ballan holds an LL. B
degree from Essex University,
UK, and an LL.M degree from New York University Faculty of Law.
Item 9.01 – FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
The following Exhibits are filed as part of this Current Report.
Exhibit
Number |
Description | |
10.1 | Board of Directors Resolution Appointing Independent Directors. |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: June 25, 2019 | CANNABICS PHARMACEUTICALS, INC. | |
By: | /s/ Eyal Barad | |
Name: | Eyal Barad | |
Title: | Chief Executive Officer |
3 |
1 Year CNBX Pharmaceuticals (QB) Chart |
1 Month CNBX Pharmaceuticals (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions